Equity Profile

RCUS

Arcus Biosciences, Inc.

Health CareBiotechnology$2.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcus Biosciences, Inc. (RCUS) operates in the biotechnology sector, focusing on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Arcus Biosciences, Inc. (RCUS) operates in the biotechnology sector, focusing on developing innovative cancer therapies. With a market cap of $3 billion, the company is part of a critical industry that aims to improve patient outcomes through advanced medical treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Arcus reported an EPS of -$1.02, which was worse than the expected -$0.92, resulting in a slight stock increase of 0.04% the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Focus on advancing clinical trials for their cancer therapies.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's recent performance and the lack of analyst estimates. The market is watching closely for any signs of improvement in profitability and revenue.

Bull Case

If Arcus can demonstrate significant progress in its clinical trials and show better-than-expected EPS, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, particularly in EPS or revenue growth, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026, and how does it compare to previous estimates?

The EPS figure will be crucial in determining the company's financial health and could significantly influence investor sentiment.

What updates can management provide on the progress of their clinical trials?

Progress in clinical trials is vital for the company's future growth and could impact stock performance based on investor expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcus to surprise on the upside with clinical trial results, which could significantly impact future revenue streams.

Supporting Evidence

The company's recent history shows a 75% EPS beat rate, suggesting potential for positive surprises.

Options pricing indicates a significant move, which may reflect investor anticipation of unexpected news.

Key Risk

If clinical trial updates indicate faster progress than anticipated, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in assessing whether the company can turn around its recent trends of underperformance.

Bull Confirmed If

An EPS of -$0.80 or better, along with positive updates on clinical trial progress.

Bear Confirmed If

An EPS worse than -$1.00, indicating ongoing struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±34.2%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats EPS expectations, history suggests a potential stock increase of around 1.35%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

A miss on EPS could lead to a decline of approximately 4.57%, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on clinical trial timelines and results.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations in the pipeline.
4Details on market demand for their cancer therapies.
5Any changes to long-term financial guidance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcus Biosciences, Inc. (RCUS) operates in the biotechnology sector, focusing on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for their cancer therapies.
Commitment to improving operational efficiencies.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Bull Case

If Arcus can demonstrate significant progress in its clinical trials and show better-than-expected EPS, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, particularly in EPS or revenue growth, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026, and how does it compare to previous estimates?

The EPS figure will be crucial in determining the company's financial health and could significantly influence investor sentiment.

What updates can management provide on the progress of their clinical trials?

Progress in clinical trials is vital for the company's future growth and could impact stock performance based on investor expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcus to surprise on the upside with clinical trial results, which could significantly impact future revenue streams.

Supporting Evidence

The company's recent history shows a 75% EPS beat rate, suggesting potential for positive surprises.

Options pricing indicates a significant move, which may reflect investor anticipation of unexpected news.

Key Risk

If clinical trial updates indicate faster progress than anticipated, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in assessing whether the company can turn around its recent trends of underperformance.

Bull Confirmed If

An EPS of -$0.80 or better, along with positive updates on clinical trial progress.

Bear Confirmed If

An EPS worse than -$1.00, indicating ongoing struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±34.2%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats EPS expectations, history suggests a potential stock increase of around 1.35%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

A miss on EPS could lead to a decline of approximately 4.57%, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on clinical trial timelines and results.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations in the pipeline.
4Details on market demand for their cancer therapies.
5Any changes to long-term financial guidance.